BeOne Medicines (NASDAQ:ONC) CFO Sells $162,633.94 in Stock

by · The Markets Daily

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CFO Aaron Rosenberg sold 631 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $257.74, for a total transaction of $162,633.94. Following the transaction, the chief financial officer directly owned 397,891 shares of the company’s stock, valued at approximately $102,552,426.34. This represents a 0.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

BeOne Medicines stock traded up $3.72 on Monday, reaching $268.20. 351,440 shares of the stock were exchanged, compared to its average volume of 258,341. The stock has a market cap of $29.43 billion, a PE ratio of 60.00 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22. The firm has a fifty day moving average price of $298.56 and a two-hundred day moving average price of $314.03.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently modified their holdings of the stock. Cetera Investment Advisers acquired a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $455,000. Rhumbline Advisers acquired a new stake in BeOne Medicines in the 2nd quarter valued at $275,000. Arrowstreet Capital Limited Partnership acquired a new stake in BeOne Medicines in the 2nd quarter valued at $505,000. Invesco Ltd. acquired a new stake in BeOne Medicines in the 2nd quarter valued at $422,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in BeOne Medicines in the 2nd quarter valued at $68,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on ONC. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BeOne Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

View Our Latest Stock Report on BeOne Medicines

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Read More